Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 4/20 | 0.43 |
| ▸ | HPGDS | O60760 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11945837 | 0.89 | NPBWR1 (0.48) | NPBWR1MCHR1TP53HPGDSLMNA | |
| SCHEMBL11945834 | 0.89 | NPBWR1 (0.48) | NPBWR1MCHR1TP53HPGDSLMNA | |
| SCHEMBL14081413 | 0.78 | TP53 (0.44) | NPBWR1MCHR1TP53HPGDSLMNA | |
| SCHEMBL17058437 | 0.77 | ALDH1A1 (0.40) | NPBWR1MCHR1TP53MAPTSMN1; SMN2 | |
| SCHEMBL17057942 | 0.75 | POLB (0.42) | NPBWR1MCHR1TP53HPGDSLMNA | |
| SCHEMBL17058163 | 0.74 | ALDH1A1 (0.36) | NPBWR1MCHR1SMN1; SMN2 | |
| SCHEMBL17058109 | 0.73 | ALDH1A1 (0.33) | NPBWR1MCHR1SMN1; SMN2 | |
| SCHEMBL11944477 | 0.73 | POLB (0.37) | NPBWR1MCHR1HPGDSLMNAMAPT | |
| SCHEMBL11944476 | 0.73 | SLC2A1 (0.33) | NPBWR1MCHR1TP53HPGDSLMNA | |
| SCHEMBL17058415 | 0.73 | SLC2A1 (0.37) | NPBWR1MCHR1LMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232274-B2 | Pyridazinone derivatives useful as glucan synthase inhibitors | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232274-B2 | Pyridazinone derivatives useful as glucan synthase inhibitors | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | MAN2A1, GYS2, MANBA | NPBWR1 4643/4885MCHR1 4513/4885TP53 3492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.